Edition:
India

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

2.30USD
18 Apr 2019
Change (% chg)

$-0.01 (-0.43%)
Prev Close
$2.31
Open
$2.31
Day's High
$2.38
Day's Low
$2.24
Volume
36,666
Avg. Vol
149,859
52-wk High
$16.47
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences Initiates Head-To-Head Clinical Trial (Compare) Of SEL-212 vs KRYSTEXXA
Friday, 29 Mar 2019 

March 29 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES INITIATES HEAD-TO-HEAD CLINICAL TRIAL (COMPARE) OF SEL-212 VERSUS. KRYSTEXXA® IN PATIENTS WITH CHRONIC REFRACTORY GOUT AND STRENGTHENS MANAGEMENT TEAM.SELECTA BIOSCIENCES - COMPARE TRIAL PRIMARY ENDPOINT IS EXPECTED TO BE MAINTENANCE OF SERUM URIC ACID LEVELS OF <6MG/DL AT 6 MONTHS.SELECTA BIOSCIENCES - COMPARE TRIAL INTERIM 6-MONTH DATA READOUT EXPECTED IN Q4 2019,FULL STATISTICAL SUPERIORITY DATA ANALYSIS READOUT EXPECTED IN Q1 2020.SELECTA BIOSCIENCES - COMPARE TRIAL RESULTS EXPECTED TO INFORM DESIGN OF PLANNED PHASE 3 SEL-212 CLINICAL TRIAL , WHICH CO PLANS TO INITIATE IN Q4 2019.  Full Article

Selecta Biosciences Q4 Loss Per Share $0.65
Friday, 15 Mar 2019 

March 15 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.65.Q4 REVENUE $900,000.Q4 REVENUE ESTIMATE $0 -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.70 -- REFINITIV IBES DATA.COLLABORATION WITH CURECN PROJECTED TO DOSE FIRST PATIENT WITH COMBINATION OF IMMTOR + AAV GENE THERAPY CANDIDATE IN 2H19.SELECTA BIOSCIENCES - PHASE 2 HEAD-TO-HEAD CLINICAL TRIAL OF SEL-212 VERSUS KRYSTEXXA TO BEGIN IN 1Q19, INTERIM SIX-MONTH DATA EXPECTED IN 4Q19.COMPANY RAISES $33M IN GROSS OFFERING PROCEEDS AND $31.3M IN NET PROCEEDS IN 1Q19, CASH RUNWAY INTO 1Q20.HAD CASH, CASH EQUIVALENTS AND RESTRICTED CASH OF $37.7 MILLION AS OF DEC 31, 2018 VERSUS $50.5 MILLION AT SEPT 30, 2018.  Full Article

Selecta Biosciences Announces Pricing Of Public Offering Of Common Stock
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 20.0 MILLION COMMON SHARES PRICED AT $1.50PER SHARE.  Full Article

Selecta Biosciences Announces Proposed Public Offering Of Common Stock
Wednesday, 23 Jan 2019 

Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SELECTA BIOSCIENCES - INTENDS TO USE NET PROCEEDS, WITH EXISTING CASH RESOURCES, TO ADVANCE CLINICAL DEVELOPMENT OF SEL-212.  Full Article

Selecta Biosciences Says Workforce Reduction Resulted In Termination Of About 17 Employment Positions
Friday, 4 Jan 2019 

Jan 3 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES INC - WORKFORCE REDUCTION RESULTED IN TERMINATION OF APPROXIMATELY 17 EMPLOYMENT POSITIONS EFFECTIVE JANUARY 3, 2019.SELECTA BIOSCIENCES INC - WORKFORCE REDUCTION PRIMARILY AFFECTED THOSE WORKING IN RESEARCH AND RELATED GENERAL AND ACCOUNTING FUNCTIONS.SELECTA BIOSCIENCES INC - FOLLOWING WORKFORCE REDUCTION, EXPECTS TO HAVE APPROXIMATELY 45 FULL-TIME EMPLOYMENT POSITIONS.SELECTA BIOSCIENCES INC - WILL INCUR AGGREGATE CHARGES IN CONNECTION WITH WORKFORCE REDUCTION OF ABOUT $488,000.SELECTA BIOSCIENCES INC - EXPECTS TO SUBSTANTIALLY COMPLETE WORKFORCE REDUCTION DURING Q1 OF 2019.  Full Article

Selecta Biosciences - Restructuring To Reduce Current Workforce By 36 Percent As Of January 3, 2019
Friday, 4 Jan 2019 

Jan 3 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES EXPANDS POTENTIAL FOR IMMTOR™ PLATFORM AND STREAMLINED STRUCTURE UNDER LEADERSHIP OF NEW CEO, CARSTEN BRUNN, PH.D..SELECTA BIOSCIENCES INC - RESTRUCTURING TO REDUCE CURRENT WORKFORCE BY 36% AS OF JANUARY 3, 2019.SELECTA BIOSCIENCES INC - HEAD-TO-HEAD SUPERIORITY TRIAL FOR SEL-212 VERSUS. KRYSTEXXA® EXPECTED TO BEGIN IN Q1 2019.SELECTA BIOSCIENCES INC - PLANS TO DEPRIORITIZE ITS SEL-403 PHASE 1 ONCOLOGY PROGRAM.SELECTA BIOSCIENCES - REDUCTION COUPLED WITH REPRIORITIZATION OF CO'S PIPELINE PROGRAMS IS PROJECTED TO REDUCE YEARLY CASH BURN BY 19% GOING FORWARD.SELECTA BIOSCIENCES INC - EFFECTIVE DECEMBER 1, 2018, CARSTEN BRUNN, ASSUMED ROLE OF PRESIDENT AND CEO OF SELECTA.SELECTA - WORKFORCE REDUCTION, COUPLED WITH REPRIORITIZATION OF CO'S PIPELINE PROGRAMS, PROJECTED TO REDUCE YEARLY CASH BURN BY 19% GOING FORWARD.SELECTA BIOSCIENCES - EXPECTS CURECN TO INITIATE PRECLINICAL TOXICOLOGY STUDIES IN H1 2019 & FOR COMBINATION PRODUCT CANDIDATE TO ENTER CLINIC IN H2.  Full Article

Selecta Biosciences reports Q3 results
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.71.Q3 EARNINGS PER SHARE VIEW $-0.75 -- THOMSON REUTERS I/B/E/S.  Full Article

Selecta Biosciences Qtrly Loss Per Share $0.88
Thursday, 15 Mar 2018 

March 15 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 REVENUE $100,000 VERSUS $2.9 MILLION.Q4 REVENUE VIEW $5.3 MILLION -- THOMSON REUTERS I/B/E/S.PHASE 1 CLINICAL TRIAL OF SEL-403 FOR MESOTHELIOMA INITIATED.REPORTS YEAR-END 2017 CASH OF $97 MILLION AND REITERATES RUNWAY THROUGH MID-2019.QTRLY LOSS PER SHARE $0.88.  Full Article

Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING.SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019.  Full Article

Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY.SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018.  Full Article